trending Market Intelligence /marketintelligence/en/news-insights/trending/cPnn4C9LR6MQesVs21xYcA2 content esgSubNav
In This List

Denali Therapeutics closes IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Denali Therapeutics closes IPO

Denali Therapeutics Inc. closed its IPO of 15,972,221 common shares at $18 per share.

The shares sold included the full exercise of the underwriters' option to buy up to 2,083,333 additional shares.

Denali's shares started trading on Nasdaq on Dec. 8, closing at $21.45 on the first day of trading with a volume of 3,907,900 shares.

Goldman Sachs & Co. LLC, Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering, and Evercore Group LLC acted as lead manager for the offering.